JAVELIN MEDLEY
12 Apr 2022
Trial Summary
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
Acronym:
JAVELIN Medley
ACTRN/NCT /ethics:
NCT05327530
Scientific title:
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line PlatinumContaining Chemotherapy
Sponsor / Cooperative group:
EMD Serono Research & Development Institute, Inc.
Trial & Patient Characteristics
| Cancer Type | Bladder |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Urothelial |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-08-17 |
| Anticipated End Date | 2026-08-05 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Francis Parnis |
| Recruitment Status | Recruiting |